Patents by Inventor Nelson Hsia

Nelson Hsia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    Publication number: 20240110184
    Abstract: Aspects of the disclosure relate to oligonucleotides (e.g., RNAi oligonucleotides such as siRNAs) designed to target DUX4 RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease (e.g., FSHD).
    Type: Application
    Filed: December 30, 2021
    Publication date: April 4, 2024
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Duncan Brown, Nelson Hsia, Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Methods of treating tissue calcification
    Patent number: 10493135
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 3, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill
  • Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)
    Patent number: 10413597
    Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 17, 2019
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
  • METHODS OF TREATING TISSUE CALCIFICATION
    Publication number: 20180318400
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 8, 2018
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W.Charles O'Neill
  • TRUNCATED LYSOSOMAL ACID LIPASE
    Publication number: 20170266264
    Abstract: Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods of producing TLAL are further disclosed.
    Type: Application
    Filed: December 21, 2016
    Publication date: September 21, 2017
    Inventors: Erin Renae Treece, Nelson Hsia, Zhinan Xia, Anthony Quinn
  • METHODS OF TREATING MUCOPOLYSACCHARIDOSIS IIIB (MPSIIIB)
    Publication number: 20170216413
    Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.
    Type: Application
    Filed: September 29, 2015
    Publication date: August 3, 2017
    Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
  • TRUNCATED LYSOSOMAL ACID LIPASE
    Publication number: 20150098933
    Abstract: Recombinant human lysosomal acid lipase (rhLAL) containing an N-terminal truncation, a composition of truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL and at least one other form of rhLAL are disclosed. A method of purifying TLAL from a mixture of LAL proteins, pharmaceutical compositions comprising TLAL and methods of producing TLAL are further disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: April 9, 2015
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Erin Renae Treece, Nelson Hsia, Zhinan Xia, Anthony Quinn
  • Methods of treating tissue calcification
    Patent number: RE49529
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 16, 2023
    Assignee: Inozyme Pharma, Inc.
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill